Erysipelothrix rhusiopathiae is a Gram-positive bacillus that is infrequently responsible for infections in humans. Three forms have been classified: a localized cutaneous form (erysipeloid) caused by traumatic penetration of E. rhusiopathiae, a generalized cutaneous form and a septicemic form. The latter type of disease has been previously associated with a high incidence of endocarditis. Here we report a case of E. rhusiopathiae bacteremia in a 74-year-old man, probably started from an erysipeloid form, in which endocarditis did not develop. This case presents some particular and uncommon features: i) no correlation with animal source; ii) correlation between bacteremia and erysipeloid lesion; iii) absence of endocarditis. MALDI-TOF mass spectrometry allowed to obtain a rapid identification (within 4 hours from bottle positivity) of E. rhusiopathiae. Together with direct antimicrobial susceptibility testing, this approach could improve the rate of appropriate therapy for bloodstream infections due to this fastidious pathogen.
We read with interest the article by Caselli D et al., reporting a case series of 38 children with chilblain‐like lesions (CLL). Testing for SARS‐CoV‐2, including PCR, rapid test serology and ELISA method for IgA and IgG antibodies yielded negative results in all cases. They concluded that their data do not allow them to support the relationship of CLL with SARS‐CoV‐2 infection. So far, data in the literature studying CLL documented a very low percentage of laboratory confirmed SARS‐CoV‐2. However, Colmenero and colleagues were able to detect SARS‐CoV‐2 in endothelial cells of cutaneous chilblain lesions by immunohistochemistry methods in 7 pediatric patients with negative nasopharyngeal swabs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.